

The full list of AbbVie presentations at IMS includes:

Note: All presentation times are listed in local Glasgow time.

Abstract Title	Date/Time	Session	Abstract Number
Real-World (RW) Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) in Europe: Results from the HARMONY BigData Platform	Wednesday, September 23, 2026 12:00–1:00 PM	Poster Presentation	PA-386
Etentamig in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to B-Cell Maturation Antigen (BCMA)-Targeted Therapy	Thursday, September 24, 2026 12:00–1:00 PM	Poster Presentation	PA-181
A Phase 1/2, Open-Label, Platform Study to Evaluate the Safety and Efficacy of Etentamig Monotherapy or Combination Therapy in Patients with Multiple Myeloma	Friday, September 25, 2026 12:00–1:00 PM	Poster Presentation	PA-008
Phase 1/2, Open-Label, Platform Study of Surzetoclax with Etentamig in Biomarker-Selected Patients with Relapsed/Refractory Multiple Myeloma (RRMM)	Friday, September 25, 2026 12:00–1:00 PM	Poster Presentation	PA-346
Real-World (RW) Infection-Related Healthcare Resource Utilization (HCRU) and Costs in Patients (pts) with Multiple Myeloma (MM) Receiving T-cell Redirecting Therapies (TCRTs)	Friday, September 25, 2026 12:00–1:00 PM	Poster Presentation	PA-387
CERVINO: Phase (Ph) 3 Results of Etentamig vs Investigator's Choice of Standard Available Therapies (SAT) in Patients (Pts) With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma (RRMM)	Friday, September 25, 2026 3:00–5:00 PM	Plenary Session Hall 5	LBA-01

Etentamig Combined With Pomalidomide Plus Dexamethasone (Pom+Dex) in Relapsed/Refractory Multiple Myeloma (RRMM) After 1–3 Prior Lines of Therapy: A Phase 1b Dose- Escalation and Safety Expansion Study	Saturday, September 26, 2026 8:30–9:30 AM	Oral Presentation Abstract Session 9 Hall 5	OA-24
AbbVie Advances ABBV-2001/ISB 2001: A Unique, Single-Molecule Trispecific T-cell Engager (TCE) Approach Toward Robust Anti-Myeloma Activity with Superior Tumor Cytotoxicity	Saturday, September 26, 2026 9:30–10:20 AM	Oral Presentation Future Targets and New Modalities of Therapy Hall 5	N/A
Surzetoclax: A Potentially Best-in-Class BCL-2 Inhibitor for the Treatment of Multiple Myeloma with t(11;14) Translocation or High BCL-2 Expression	N/A	Poster Presentation	PA-468